Parvovirus B19 and Parvovirus 4 infections among healthy blood donors; A prevalence report from Iran.

Blood donors Bloodborne pathogens Parvovirus 4 (PARV4) Parvovirus B19 (B19V) Prevalence report Real-Time PCR Seroprevalence Transfusion-transmitted infections

Journal

IDCases
ISSN: 2214-2509
Titre abrégé: IDCases
Pays: Netherlands
ID NLM: 101634540

Informations de publication

Date de publication:
2024
Historique:
received: 13 09 2023
revised: 30 07 2024
accepted: 03 08 2024
medline: 2 9 2024
pubmed: 2 9 2024
entrez: 2 9 2024
Statut: epublish

Résumé

Parvoviruses, characterized by their tropism for blood cells, can manifest as asymptomatic infections. With their ability to persist in blood, assessing the prevalence of Parvovirus B19 (B19V) and Parvovirus 4 (PARV4) among healthy blood donors is essential for evaluating the potential transmission risks through blood transfusions, emphasizing the need for comprehensive screening protocols. Four hundred blood donors participated in the study, with their blood specimens subjected to Real-Time PCR analysis for B19V and PARV4 nucleic acids after obtaining informed consent. Additionally, Complete Blood Count (CBC) assessments and determination of anti-B19 V-IgM and anti-B19 V-IgG antibody titers were performed using Enzyme-Linked Immunosorbent Assay (ELISA) for all collected samples. The results reveal that 12 out of 400 individuals (3 %) exhibited positive results for B19V DNA, while 6 out of 400 individuals (1.5 %) tested positive for PARV4 DNA. Additionally, 8 out of 400 individuals (2 %) displayed positive results for anti-B19V IgM, and 306 out of 400 individuals (76.5 %) exhibited positive results for anti-B19 IgG. Notably, one donation from a donor presenting anti-IgM antibodies was subsequently confirmed as B19V DNA-positive through Real-Time PCR. In the analysis of CBC, a significant disparity in platelet levels was observed between B19V-positive donors, PARV4-positive donors, and B19V-negative donors. The study suggests that individuals at high risk, lacking detectable B19V antibodies, should undergo systematic screening and exclusion. This precaution is intended to minimize potential contamination risks within the studied cohort, despite the undefined pathogenesis and clinical implications of PARV4.

Sections du résumé

Background UNASSIGNED
Parvoviruses, characterized by their tropism for blood cells, can manifest as asymptomatic infections. With their ability to persist in blood, assessing the prevalence of Parvovirus B19 (B19V) and Parvovirus 4 (PARV4) among healthy blood donors is essential for evaluating the potential transmission risks through blood transfusions, emphasizing the need for comprehensive screening protocols.
Methods UNASSIGNED
Four hundred blood donors participated in the study, with their blood specimens subjected to Real-Time PCR analysis for B19V and PARV4 nucleic acids after obtaining informed consent. Additionally, Complete Blood Count (CBC) assessments and determination of anti-B19 V-IgM and anti-B19 V-IgG antibody titers were performed using Enzyme-Linked Immunosorbent Assay (ELISA) for all collected samples.
Results UNASSIGNED
The results reveal that 12 out of 400 individuals (3 %) exhibited positive results for B19V DNA, while 6 out of 400 individuals (1.5 %) tested positive for PARV4 DNA. Additionally, 8 out of 400 individuals (2 %) displayed positive results for anti-B19V IgM, and 306 out of 400 individuals (76.5 %) exhibited positive results for anti-B19 IgG. Notably, one donation from a donor presenting anti-IgM antibodies was subsequently confirmed as B19V DNA-positive through Real-Time PCR. In the analysis of CBC, a significant disparity in platelet levels was observed between B19V-positive donors, PARV4-positive donors, and B19V-negative donors.
Conclusions UNASSIGNED
The study suggests that individuals at high risk, lacking detectable B19V antibodies, should undergo systematic screening and exclusion. This precaution is intended to minimize potential contamination risks within the studied cohort, despite the undefined pathogenesis and clinical implications of PARV4.

Identifiants

pubmed: 39220424
doi: 10.1016/j.idcr.2024.e02055
pii: S2214-2509(24)00131-8
pmc: PMC11364128
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e02055

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mohammad Mehdi Sabahi (MM)

Department of Neurological Surgery, Pauline Braathen Neurological Center, Cleveland Clinic Florida, Weston, FL, USA.

Mehrdad Mosadegh (M)

Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.

Azin Kazemi (A)

Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Islamic Republic of Iran.

Razieh Amini (R)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Islamic Republic of Iran.

Shahab Mahmoudvand (S)

Department of Virology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Islamic Republic of Iran.

Mojtaba Hedayat Yaghoubi (M)

Department of Infectious Disease, Faculty of Medicine, Alborz University of Medical Sciences, Alborz, Islamic Republic of Iran.

Mohammad Masoud Maleki (MM)

Molecular Diagnosis Department, Farzan Molecular and Pathobiology Laboratory, Hamadan, Islamic Republic of Iran.

Zahra Sanaei (Z)

Department of Community Medicine, Hamadan University of Medical Science, Hamadan, Islamic Republic of Iran.

Farid Azizi Jalilian (F)

Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Islamic Republic of Iran.
Molecular Diagnosis Department, Farzan Molecular and Pathobiology Laboratory, Hamadan, Islamic Republic of Iran.

Classifications MeSH